Contact Us
+1877- DYNAMILL (3962 6455)
Our Location
16W285 83rd St. STE D-1 Burr Ridge, IL 60527
info@dynamillcro.com
Social Network
Close
An IVD clinical performance study evaluates whether an in vitro diagnostic test performs as intended in the target population and clinical setting. For FDA, IVDR, and global regulatory planning, sponsors should be prepared to generate evidence around intended use, analytical performance, clinical performance, sensitivity, specificity, comparator methods, specimen handling, data quality, and regulatory-ready reporting.
A strong IVD evidence package should show not only that the test works, but that it works reliably for the people, specimens, operators, and settings described in the intended use.
An IVD clinical performance study is designed to evaluate the clinical performance of an in vitro diagnostic device. In simple terms, it helps answer the question: does this test perform as intended in real clinical use?
An IVD may be used to detect, screen, diagnose, monitor, or support treatment decisions. The clinical performance study must be designed around the specific intended use of the test.
For example, an IVD study may evaluate:
The study design depends on what the test is intended to do and how the result will be used.
IVD sponsors often focus heavily on product development, assay optimization, and analytical performance. These are essential, but they are not the full evidence story.
Regulators, clinicians, laboratories, and commercial partners need to understand how the test performs in real use.
Clinical evidence helps answer questions such as:
Without a strong IVD clinical performance study, even a promising diagnostic technology may face regulatory delays, adoption barriers, or payer skepticism.
FDA and IVDR are different regulatory systems, but both require sponsors to think carefully about evidence.
For FDA planning, IVD sponsors may need to consider the appropriate pathway, such as 510(k), De Novo, PMA, CLIA waiver, or other applicable requirements. The evidence package must support the test’s intended use, performance claims, and regulatory submission strategy.
For IVDR, clinical evidence is commonly discussed through three core pillars:
Together, these help demonstrate that the IVD is supported by sufficient evidence for its intended purpose.
Even if a sponsor is initially focused on the U.S. market, understanding global evidence expectations can help build a stronger long-term development strategy.
One of the most common areas of confusion in IVD development is the difference between analytical performance and clinical performance.
Analytical performance looks at how well the test measures or detects the target analyte under defined conditions.
It may include:
Analytical performance helps show whether the test can technically detect what it is designed to detect.
Clinical performance evaluates how the test result relates to the clinical condition, disease state, or intended clinical use.
It may include:
Clinical performance helps show whether the test result is meaningful and reliable in the intended population.
Both are important. A technically strong test still needs clinical evidence to support its use.
Mistake 1: Starting Without a Clear Intended Use
The intended use should guide the whole study. If it is not clear, the study may collect data that does not fully support the claim.
Mistake 2: Underestimating Specimen Logistics
Specimen collection, labeling, processing, shipping, and storage must be carefully controlled. Poor specimen handling can compromise data quality.
Mistake 3: Choosing the Wrong Comparator
The comparator must be scientifically and clinically appropriate. Sponsors should not treat comparator selection as an administrative task.
Mistake 4: Selecting Sites Based Only on Enrollment Potential
Fast enrollment is helpful, but site quality matters. For IVD studies, poor workflow execution can produce unreliable results.
Mistake 5: Reviewing Data Too Late
Data should be reviewed throughout the study. Waiting until the end may lead to avoidable delays, rework, or data loss.
An experienced IVD CRO can help sponsors plan and execute clinical performance studies more effectively. Dynamill Research supports IVD clinical studies through:
The right IVD CRO services can reduce operational uncertainty and improve submission readiness.
Contact Us
+1877- DYNAMILL (3962 6455)
Our Location
16W285 83rd St. STE D-1 Burr Ridge, IL 60527
info@dynamillcro.com
Social Network
An IVD clinical performance study evaluates how an in vitro diagnostic test performs in the intended population and clinical setting.
Analytical performance evaluates how well a test detects or measures the target analyte. Clinical performance evaluates how well the test result relates to the clinical condition or intended use.
Common metrics include sensitivity, specificity, PPV, NPV, positive percent agreement, negative percent agreement, invalid rate, and reproducibility.
Specimen handling affects test performance and data integrity. Incorrect sample type, delayed processing, temperature excursions, or poor labeling can compromise study results.
An IVD CRO can support study design, site selection, specimen logistics, comparator oversight, monitoring, data management, and regulatory-ready reporting.